The resignation is effective from the close of business hours on August 31, 2026. The reason for her resignation is her appointment to a regional role within the parent AstraZeneca Group.
The disclosure includes two annexures:
- Annexure A: A copy of the resignation letter submitted by Ms. Agrawal.
- Annexure B: Details required under the SEBI Master Circular SEBI/HO/49/14/14(7)2025- CFD-POD2/I/3762/2026 dated January 30, 2026.
Details from Annexure B (Disclosure Table):
- Reason for change: Resignation from the position of Chief Financial Officer.
- Date of Cessation: Close of business hours on August 31, 2026.
- Brief Profile: Not applicable.
- Shareholding in the Company: NIL.
- Disclosure of Relationships between Directors: Not applicable.
The resignation letter from Ms. Agrawal, addressed to the Managing Director and the Board, formally requests acceptance of her resignation and expresses thanks to the Board, senior management team, and colleagues for their support during her tenure.
The regulatory filing was signed and submitted digitally by Tanya Sanish, Company Secretary & Compliance Officer (ACS No. 25784), on behalf of AstraZeneca Pharma India Limited.